OKO. V. Kotsar

O. V. Kotsar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


O. V. Kotsar has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • CRISPR-EDITED COMMENSALS OF THE NASOPHARYNX AS PLATFORM FOR DEVELOPING NEXT-GENERATION MICROBIAL PROBIOTICS

    by Yaroslav Bondarenko, Olena Kochnieva, Olena Kotsar, Oksana Kauk, Olena Pionova, Oksana Tsyhanenko, Petro Lebid, Milena Kuznetsova, Iryna Kuznietsova, Maksym Kovalov

    Background. The nasopharynx is a critical mucosal barrier where commensals maintain immune balance and prevent pathogen colonization. Corynebacterium accolens and Dolosigranulum pigrum are linked to reduced pneumococcal carriage, fewer viral–bacterial coinfections, and modulation of host immunity. Their metabolites—short-chain fatty acids, nitric oxide, bacteriocins—reinforce epithelial integrity and regulate NF-κB, JAK/STAT, TGF-β/STAT3, promoting Treg cells. Natural effects remain insufficient for therapy. CRISPR/Cas now enables programming these commensals into “living probiotics” that deliver therapeutic molecules in a context-specific manner. Objective: To evaluate C. accolens and D. pigrum as microbial therapy candidates and propose a CRISPR/Cas9 framework for engineering probiotics to modulate mucosal immunity, exclude pathogens, and transmit anti-inflammatory signals. Methods. A systematic review (2005-2025) was conducted in PubMed, Scopus, Web of Science, EMBASE, Google Scholar using terms: “nasopharyngeal microbiome,” “C. accolens,” “D. pigrum,” “CRISPR editing,” “probiotics,” “mucosal immunity.” Eligible studies covered genomic, proteomic, metabolomic features, immune interactions, CRISPR editing in probiotics, and preclinical/in silico models. Excluded: unrelated niches, insufficient methods, and non-CRISPR work. Data were synthesized into five topics: ecological roles, molecular/secretome features, CRISPR advances, biosafety design, and validation strategies. Results. Both taxa emerged as keystone members of the nasopharyngeal microbiome. Genomics revealed stable chromosome organization, no virulence genes, and pathways for SCFA biosynthesis, lipid metabolism, and adhesion. Proteomic and metabolomic studies confirmed secretion of antimicrobial peptides, bacteriocins, and nitric oxide, reducing pathogens and modulating immunity. Functional assays showed TLR2/6 activation, NF-κB inhibition, STAT3/TGF-β promotion, and IL-10 induction, strengthening barriers, enhancing IgA, and favoring regulatory immunity. A CRISPR design was proposed for C. accolens, featuring an IL-10 cassette under an inflammation-inducible promoter, kill switches, auxotrophy, and self-limiting nuclease activity. In silico modeling confirmed ecological compatibility and circuit stability. Validation was conducted across in silico prediction, in vitro epithelium–MALT co-cultures, and in vivo murine models, with checkpoints for genomic stability, tolerance, and the absence of systemic spread. Personalization included microbiome-guided strain selection, prebiotic co-formulation, and biofilm assays, ensuring therapeutic expression only under inflammation. Conclusions. CRISPR-edited nasopharyngeal commensals are a promising therapeutic platform. C. accolens and D. pigrum combine stability, safety, and intrinsic immunomodulatory capacity, amplified by precise engineering. Inflammation-inducible IL-10 circuits enable localized, context-specific mucosal immunomodulation. Biosafety modules minimize ecological risk and secure evolutionary stability. Such engineered strains may deliver robust, personalized, clinically relevant interventions for infectious and inflammatory airway diseases.


  • Open Access

    KLEBSIELLA PNEUMONIAE – ПРОВІДНИЙ ЗБУДНИК РАНОВОЇ ІНФЕКЦІЇ

    by О. В. Коцар, О. В. Кочнєва

    Мета роботи – визначення мікробіому ранової інфекції, вивчення чутливості клінічних ізолятів K. pneumoniae до дії антибактерійних препаратів різних груп. Пацієнти і методи. У дослідженні взяли участь 96 пацієнтів з рановою інфекцією, яка виникла внаслідок мінно-вибухових травм (чоловіки віком від 20 до 45 років). Основними критеріями відбору були статус пацієнта як військовослужбовця, факт отримання пацієнтом мінно-вибухової травми в умовах бойових дій, наявність результатів мікробіологічного дослідження рани, що розглядалося як ознака інфекційного процесу чи підозри на нього. Аналіз мікробіому ранової інфекції здійснювали бактеріологічним методом дослідження, а визначення чутливості до антибіотиків – диско-дифузійним методом. Результати досліджень та їх обговорення. З ранового вмісту від поранених хворих було виділено 46 штамів, серед яких в 39,0 % випадків провідним етіологічним фактором ранової інфекції була K. pneumoniae, в 28,0 % – S. аureus, P. aeruginosa (13,0 %), Acinetobacter spp. (8,7 %), а частка виділених штамів E. faecalis та E. coli була 4,3 та 6,5 % відповідно. Найвища антибіотикорезистентність до різних класів антибактерійних препаратів спостерігалась у половини ізольованих культур K. pneumoniae, серед яких превалювали полірезистентні штами. Висновки. Аналіз рівня антибіотикочутливості ізольованих клінічних штамів K. pneumoniae продемонстрував низькі показники. Найбільш чутливі штами K. pneumoniae виявилися до амікацину та гентаміцину (у 45,4 %), чутливість до піперациліну/тазобактаму була 36,3 %, а кількість чутливих штамів до цефтазидиму, меропенему, левофлоксацину та ципрофлоксацину становила 27,2 %. Слабшою активністю володіли антибіотики амоксицилін, ампісульбін, цефтріаксон, цефепім, цефоперазон, цефепім, цефотаксим, імепенем, чутливість до яких становила майже 9 %.

  • Open Access

    Producing metabolic complexes of probiotic microorganisms with significant antimicrobial properties

    by O. Yu. Isaienko, O. V. Kotsar, T. M. Ryzhkova, H. I. Diukareva

    The aim of the work - to produce metabolic complexes with significant antibacterial properties using a new proprietary method and to substantiate the prospects of their use for designing of antimicrobial polyfunctional drugs. Materials and methods. Metabolic complexes of Lactobacillus rhamnosus GG, Lactobacillus plantarum, Saccharomyces boulardii, Enterococcus faecium were obtained by culturing the producers in ultrasonic disintegrates of other probiotic microorganisms. Sensitivity of antibiotic-resistant strains of Escherichia coli PR and Staphylococcus haemolyticus PR was determined by qualitative method. The suspension of test-cultures (optical density of 1.0 units on the McFarland scale) after incubation with metabolites (2, 24 and 48 hours at 37 degrees C) was inoculated into Mueller-Hinton agar. The absence of growth was indicative of the metabolic complexes antibacterial activity against the microorganism. Results. Cultivation of S. boulardii in the S. boulardii / L. rhamnosus / L. plantarum / E. faecium disintegrates, L. plantarum in the L. rhamnosus / E. faecium disintegrates and L. rhamnosus - in the L. plantarum disintegrates was accompanied by an increase in the biomass of isolated microorganisms (P = 0.03) and production of metabolites. Along with a similar increase in S. boulardii cells in the S. boulardii / L. rhamnosus / L. plantarum / E. faecium disintegrates, the metabolic products of lactobacterial and enterococcal disintegrates exhibited more active inhibitory effects against E. coli PR and S. haemolyticus PR. The increased antibacterial activity indicates the advantage of the new method. Another improvement is the extended spectrum of metabolic complexes owing to producer cultivation in the other probiotic disintegrates to obtain original biologically active substances with high antibacterial properties against pathogens. Among the strength of the method is that all the stages are unified into a single process avoiding multiphase procedure for the separate preparation of one probiotic microorganism disintegrate and the metabolic products of another. Conclusions. Disintegrates as a nutrient medium can be used not only for their own producers, but also for other strains/species and various probiotic microorganisms (fungi and bacteria). The increase in antibacterial activity of metabolic complexes has been found using the new method of production. The prospects of antimicrobial polyfunctional drugs designing on this basis have been proved.


  • Open Access

    Antibiotic resistant and phagosensitivity of regional strains-causative agents of pyo-inflammatory diseases (S. aureus and P. aeruginosa).

    by S.а. Dеrкаch, N.I. Gorodnicka, N.M. Kutsaj, L.S. Gabisheva, О.V. Коtsar

    Annotation. The actual issue is studying of sensitivity to antibiotics of regional strains-causative agents when there is increasing circulation of poly-resistant microorganisms. They were isolated from different biotopes. Their sensitivity to various commercial bacteriophage preparations was carried out in parallel. The purpose of the study was to determine the antibiotics of choice for starting therapy of purulent-inflammatory diseases and the prospects of using bacteriophage preparations relative to the most etiologically significant regional pathogen strains. Common methods of investigation were used: disco-diffusion to determine antibiotics sensitivity and drop method to study phagosensitivity. The results were processed by the method of variational statistics using M. Excel 2000 Biostat with Student's t test. It has been shown that antibiotics of choice for starting therapy of purulent-inflammatory diseases, in the absence of bacteriological examination of patients and determination of antibiotic sensitivity of pathogens, it is advisable to consider fluoroquinolones (sensitivity of S. aureus and P. aeruginosa to ciprofloxacin, lomefloxacin, norfloxacin about 90%), amikacin and gentamycin (78,3–39,7%), imipenem (57,4%). The conducted studies confirm the prospect of using existing bacteriophage drugs, including “Pyofag” and “Intestyfag”, LLC “Farmaxgroup” (Ukraine). The sensitivity of regional strains was 50,0–60,0%. It remains promising to study the effectiveness of the complex using of antibiotics and bacteriophages and to improve the action of commercial preparation of bacteriophages.

  • Open Access

    Simultaneous and sequential influence of metabolite complexes of Lactobacillus rhamnosus and Saccharomyces boulardii and antibiotics against poly-resistant Gram-negative bacteria

    by O. Y. Isayenko, O. V. Knysh, O. V. Kotsar, T. N. Ryzhkova, G. I. Dyukareva

    For the first time the poly-resistant strains of Gram-negative microorganisms were studied for the sensitivity to combined simultaneous and sequential influence of metabolic complexes of Lactobacillus rhamnosus GG and Saccharomyces boulardii, obtained by the author’s method without using the growth media, with antibiotics. The synergic activity of antibacterial preparations and metabolic complexes of L. rhamnosus GG and S. boulardii were studied using modified disk-diffusive method of Kirby-Bauer. During the sequential method of testing (at first the microorganisms were incubated with structural components and metabolites, then their sensitivity to the antibacterial preparations was determined), we observed increase in the diameters of the zones of growth inhibition of Pseudomonas aeruginosa PR to the typical antibiotics (gentamicin, amіcyl, ciprofloxacin, сefotaxime) and non-typical (lincomycin, levomycetin) depending on the tested combinations. Acinetobacter baumannii PR exhibited lower susceptibility: growth inhibition was seen for the combination with ciprofloxacin, сefotaxime, levomycetin. Susceptibility of Lelliottia amnigena (Enterobacter amnigenus) PR increased to levofloxacin, lincomycin. The zones of growth inhibition of Klebsiella pneumoniae PR increased to gentamicin, amіcyl, tetracycline, сeftriaxone. Maximum efficiency was determined during sequential combination of antibiotics with separate metabolic complexes of L. rhamnosus and S. boulardii, and also their combination (to 15.2, 20.2 and 15.4 mm respectively) compared with their simultaneous use (to 12.2, 15.2 and 13.0 mm respectively) for all the tested poly-resistant pathogens, regardless of the mechanism of action of antibacterial preparation. Metabolic complexes of L. rhamnosus GG and S. boulardii, due to increase in the susceptibility of microorganisms, can decrease the therapeutic concentration of antibiotic, slow the probability of the development of resistance of microorganisms, and are therefore promising candidates for developing “accompanying medications” to antibiotics and antimicrobial preparations of new generation.